title: Management of mild CA-MRSA skin infections: more complicated that it looks at a glance.
authors.forename: Andrés
authors.initials: A
authors.lastname: Pérez
authors.forename: Lourdes
authors.initials: L
authors.lastname: Orta
authors.forename: Marta
authors.initials: M
authors.lastname: Pascual
authors.forename: Emma
authors.initials: E
authors.lastname: Padilla
authors.forename: Xavier
authors.initials: X
authors.lastname: Mesquida
authors.forename: Maigualida
authors.initials: M
authors.lastname: González
authors.forename: Olga
authors.initials: O
authors.lastname: Huguet
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000891:Anti-Infective Agents, Local / Q000009:adverse effects; D001494:Baths; D002648:Child; D002710:Chlorhexidine / Q000008:administration & dosage; D017714:Community-Acquired Infections / Q000188:drug therapy / Q000382:microbiology / Q000517:prevention & control; D005667:Furunculosis / Q000188:drug therapy* / Q000382:microbiology / Q000517:prevention & control; D006801:Humans; D007223:Infant; D017053:Infection Control; D055624:Methicillin-Resistant Staphylococcus aureus; D012293:Rifampin / Q000627:therapeutic use; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000627:therapeutic use*
chemical_list: D000900:Anti-Bacterial Agents; D000891:Anti-Infective Agents, Local; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D002710:Chlorhexidine; D012293:Rifampin